Why the study?
Heart failure in cancer patients carries high morbidity and mortality, making the clinical application of recent ESC cardio-oncology guidelines essential for risk stratification, early detection, and prevention.
This review provides a practical, case-based application of the 2022 ESC Cardio-Oncology guidelines for managing cancer patients at high risk for heart failure.
Early CVD screening may benefit cancer survivors; leaves open optimal protocols for prospective validation.
Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.
No takes yet. Share an insight, caveat, or question.
Bloom et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: